Xenetic Biosciences Amends 10-K, Disclosing Significant Related Party Payments and Executive Compensation for 2025
Summary
Xenetic Biosciences filed an amended 10-K, detailing 2025 executive compensation and significant related party payments, including $0.4 million to its Chairman and $0.2 million to a director-controlled entity, which are substantial for a nano-cap company.
Key Events
-
Amended Annual Report Filed
Xenetic Biosciences, Inc. filed an Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, to include previously omitted Part III information.
-
Significant Related Party Consulting Fees
The company paid approximately $0.4 million in consulting fees to Dr. Dmitry Genkin, Chairman of the Board, during 2025 for services related to its DNase-based oncology program.
-
Related Party Clinical Trial Services
Xenetic Biosciences incurred approximately $0.2 million through December 31, 2025, under a clinical trial services agreement with PeriNess Ltd., a company where Dr. Genkin and Director Moshe Mizrahy are significant shareholders.
-
Executive Compensation Details
Interim CEO and CFO James Parslow received total compensation of $536,027 for 2025, which included a $100,000 cash retention bonus and a 20,000-share stock option grant in connection with his appointment as Interim CEO in May 2024.
Analysis
This amended annual report (10-K/A) provides previously omitted Part III information, revealing substantial related party transactions and executive compensation for fiscal year 2025. For a nano-cap company with a market capitalization of less than $7 million, the disclosure of $0.4 million in consulting fees paid to the Chairman and $0.2 million incurred with a company controlled by the Chairman and another director, alongside over $0.5 million in CEO compensation, represents a significant portion of the company's resources. While these are historical figures, their disclosure highlights considerable cash burn and potential governance concerns, which are critical for investors to consider given the company's small size and previously announced strategic review.
At the time of this filing, XBIO was trading at $3.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7M. The 52-week trading range was $1.90 to $13.93. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.